BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mederi Therapeutics Inc. Announces Receipt of CE Mark for its Second Generation Secca(R) and Stretta(R) Systems


11/8/2010 6:40:35 AM

GREENWICH, Conn., Nov. 8, 2010 /PRNewswire/ -- Mederi Therapeutics Inc announced today that it has received a CE Mark authorizing the European distribution and use of Mederi's second generation of the Stretta and Secca Systems. The Stretta System is for treatment of gastric reflux disease, commonly known as GERD, and the Secca System is for treatment of bowel control disorder, or BCD. These latest systems include a streamlined user interface, significant improvements in ease of use, and are smaller, lighter, and highly portable.

"Mederi is very pleased to offer the Stretta system for the treatment GERD and the Secca system for treatment of BCD. Mederi has made a substantial capital investment which has resulted in numerous improvements to these novel technologies," stated Will Rutan, CEO and President of Mederi Therapeutics. "The Secca and Stretta systems are ultra-minimally invasive technologies that bridge a significant gap that exists between conservative therapies and invasive surgical options for GERD and BCD. Numerous clinical studies have shown Stretta and Secca to be effective therapeutic options."

The second generation Stretta and Secca devices were launched at UEGW 2010, the annual congress of the United European Gastroenterology Federation, which was held in Barcelona, Spain, October 23-27. "It was exciting to witness the overwhelming response to Stretta and Secca, resulting in numerous requests to purchase Mederi products at the recent European congress. As the only endoluminal therapies for GERD and BCD, the interest and demand for these novel technologies is extremely high," added Rutan. Concurrent with the EU launch activities, Mederi has engaged and trained a worldwide distribution network to drive demand and ensure safe and proper use of Stretta and Secca.

The CE Mark and ISO 13485 certification demonstrate Mederi's steadfast commitment to safety and quality.

Additional information is available at www.mederitherapeutics.com.

ABOUT MEDERI

Mederi Therapeutics manufactures and markets innovative medical devices that deliver radiofrequency energy to treat disease states affecting the human digestive system. All Mederi therapies are outpatient, minimally invasive, and promote rapid recovery. Mederi Therapeutics is located in Greenwich, Connecticut.

Contact: Sheila Doyle

Manager of Communications and Marketing

203 930 9980



SOURCE Mederi Therapeutics Inc



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES